Market/Novel Tech

Coherus BioSciences, Inc. (NASDAQ: CHRS), has announced the approval of “CIMERL” a biosimilar interchangeable to Lucentis for all five indications (AMD, RVO, DME, DR and mCNV).

Coherus BioSciences, Inc. (NASDAQ: CHRS) has announced approval of CIMERLI (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all five indications  – for… Read More »Coherus BioSciences, Inc. (NASDAQ: CHRS), has announced the approval of “CIMERL” a biosimilar interchangeable to Lucentis for all five indications (AMD, RVO, DME, DR and mCNV).

Opus Genetics (Raleigh, North Carolina) has announced new preclinical data from studies evaluating gene therapies for OPGx-001 and OPGx-002.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced new preclinical data from studies evaluating gene therapies, termed… Read More »Opus Genetics (Raleigh, North Carolina) has announced new preclinical data from studies evaluating gene therapies for OPGx-001 and OPGx-002.

Regenxbio Inc.’s gene therapy treatment (RGX-314) for diabetic retinopathy (DR) reports positive interim data from Phase II.

REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, based in Rockville, Maryland, has reported positive interim data from an ongoing Phase II “ALTITUDE” trial of… Read More »Regenxbio Inc.’s gene therapy treatment (RGX-314) for diabetic retinopathy (DR) reports positive interim data from Phase II.

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA), has announced the licencing, the UK MHRA, of a biosimilar (“Ongavia”) to Lucentis (ranibizumab).

Teva Pharmaceitical (NYSE and TASE: TEVA) has announced that the UK Medicines & Healthcare Regulatory Agency (MHRA) is to grant a licence for “Ongavia”, a… Read More »Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA), has announced the licencing, the UK MHRA, of a biosimilar (“Ongavia”) to Lucentis (ranibizumab).

MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced preliminary efficacy data from a gene therapy for XLRP patients

MeiraGTx (Nasdaq: MGTX) has announced that additional clinical data from the Phase 1/2 trial of botaretigene sparoparvovec for the treatment of X-linked Retinitis Pigmentosa (XLRP)… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced preliminary efficacy data from a gene therapy for XLRP patients

Opus Genetics Inc., has announced a strategic manufacturing services agreement with National Resilience, Inc., for the development of LCA treatments

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced a strategic manufacturing services agreement with National Resilience, Inc.… Read More »Opus Genetics Inc., has announced a strategic manufacturing services agreement with National Resilience, Inc., for the development of LCA treatments

Ocugen Inc., (NASDAQ: OCGN) has announced the launch of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP)

Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced that the first patient has been dosed in a Phase 1/2 clinical… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced the launch of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP)

Aldeyra Therapeutics Inc., (NASDAQ: ALDX) reports the launch of a Phase 2 study for methotrexate to treat Pro23His retinitis pigmentosa (RP)

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a clinical stage company based in Lexington, Massachusetts, has reported the initiation of a Phase 2 clinical trial of ADX-2191… Read More »Aldeyra Therapeutics Inc., (NASDAQ: ALDX) reports the launch of a Phase 2 study for methotrexate to treat Pro23His retinitis pigmentosa (RP)

ProQR Therapeutics N.V. (NASDAQ: PRQR), announces top-line results for the treatment of a novel RNA therapy (“Sepofarsen [QR-110]”) for LCA10

A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the results of a Phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), announces top-line results for the treatment of a novel RNA therapy (“Sepofarsen [QR-110]”) for LCA10